NovoCure (NVCR) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is NVCR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fi…

Mya is an investigational product in the Optune line. These wearable devices generate electric fields that disrupt cell division, ideally preventing the spread of cancer.…

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) applic…

NovoCure (NASDAQ: NVCR - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the …

Explore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.…

NovoCure generated record third-quarter net revenue of $193 million. Active glioblastoma patients grew 11% year over year to 4,730.…

NovoCure Limited ( NVCR ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants Adam Daney - Head of Investor Relations William Doyle - Executive Chairman Frank Leonard - CEO & Director Christoph Brackm…

NovoCure NASDAQ: NVCR reported third-quarter 2026 net revenue of $193 million, up 16% from a year earlier, as growth in its Optune Gio business and an expanding launch of Optune Lua in Japan helped lift active patient co…

NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago.…

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to extend survival in some o…

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Trea…

Ambu A/S (OTCMKTS:AMBBY - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of thei…

NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption acceler…

NeurAxis (NASDAQ: NRXS - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strengt…

NovoCure (NASDAQ: NVCR - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their pro…

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable …

Corient Private Wealth LP lessened its holdings in NovoCure Limited (NASDAQ: NVCR) by 71.5% in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,650 …

NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Confe…

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.…

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonar…

Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed internal records of more than 1,400 U.S. patients.…

The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earning…

Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 10. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

